Visit 1 (Initial Visit and treatment day 0) This visit will serve as both screening and baseline. During this visit, the subject will receive the ICF and be consented in accordance to this site's consenting SOP. After consenting, inclusion and exclusion criteria will be obtained. If the subject meets these, then demographic data will be taken as well as clinical history and concomitant medications. The P.I. will then decide if the subject is to be included or excluded using the inclusion exclusion criteria, clinical history, visual examination of the head and neck, and concomitant medications. If the patient has the need for a pregnancy test, a urine pregnancy test will be performed in office. Assignment of patient # will occur as will randomization to receive Dysport® and Botox® Cosmetic in each lateral orbital area. The subject will then be photographed using the Canfield Digital photography system. The subject will provide a self-assessment of lateral orbital rhytids at rest using a static 5-point categorical scale. The investigator will assess in person lateral orbital rhytids at maximal contraction and at rest and lateral orbital rhytids according to a static 5-point Photographic scale validated in prior studies. Following the rating scales, the patient will be administered Dysport® to the lateral orbital area on one side and Botox® Cosmetic to the contralateral lateral orbital area (as described in Appendix 1 and Section 5.4). The patient is to remain for 30 minutes after injection to monitor for any AEs. A follow-up appointment at day 1 will be scheduled.